LoginSignup
Cardiff Oncology logo

Cardiff Oncology

Stock
Stock
ISIN: US14147L1089
Ticker: CRDF
US14147L1089
CRDF

Price

Price

CHART BY

Frequently asked questions

What is Cardiff Oncology's market capitalization?

The market capitalization of Cardiff Oncology is $283.37M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Cardiff Oncology?

Cardiff Oncology's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.949. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Cardiff Oncology's stock?

Currently, 5 analysts cover Cardiff Oncology's stock, with a consensus target price of $11.00. Analyst ratings provide insights into the stock's expected performance.

What is Cardiff Oncology's revenue over the trailing twelve months?

Over the trailing twelve months, Cardiff Oncology reported a revenue of $689.00K.

What is the EBITDA for Cardiff Oncology?

Cardiff Oncology's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$46.00M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Cardiff Oncology?

Cardiff Oncology has a free cash flow of -$34.65M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Cardiff Oncology have, and what sector and industry does it belong to?

Cardiff Oncology employs approximately 32 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.

What is the free float of Cardiff Oncology's shares?

The free float of Cardiff Oncology is 61.34M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$283.37M
EPS (TTM) 
-$0.949
Free Float 
61.34M
Revenue (TTM) 
$689.00K
EBITDA (TTM) 
-$46.00M
Free Cashflow (TTM) 
-$34.65M

Pricing

1D span
$4.14$4.464
52W span
$1.41$6.40

Analyst Ratings

The price target is $11.00 and the stock is covered by 5 analysts.

Buy

5

Hold

0

Sell

0

Information

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Employees
32
Industries
Medical Specialties
Sector
Health Care

Identifier

ISIN
US14147L1089
Primary Ticker
CRDF

Knockouts

Join the conversation
Sign upLogin